Fulcrum Therapeutics Inc 2025年季度报告

(Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the quarterly period endedMarch 31,2025 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the transition period fromtoCommission File Number:001-38978 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware(State or other jurisdiction of incorporation or organization)26 Landsdowne StreetCambridge,Massachusetts(Address of principal executive offices) (617)651-8851(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and(2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of April 24, 2025, the registrant had53,979,306shares of common stock, $0.001 par value per share, outstanding. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements, which reflect our current views with respect to,among other things, our operations and financial performance. All statements other than statements of historical facts contained inthis Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, futurerevenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements.The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “outlook,” “plan,”“potential,” “predict,” “project,” “should,” “target,” “would,” and the negative version of these words and other similar expressionsare intended to identify forward-looking statements, although not all forward-looking statements contain these identifying wordsand include, among other statements, express or implied statements regarding: •our ongoing clinical trial of pociredir, including the timing of data announcements and status of enrollment;•our cash runway;•the timing of and our ability to submit applications for, and obtain and maintain regulatory approvals for pociredir andany other product candidates;•our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash,cash equivalents, and marketable securities;•the initiation, timing, progress and results of our current and future preclinical studies and clinical trials (includingplanned investigational new drug, or IND, application filings) and our research and development programs, includingnovel therapeutic agents for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia, orDBA, Shwachman-Diamond syndrome, and Fanconi anemia, and other discovery programs;•our plans to develop and, if approved, subsequently commercialize pociredir and any other product candidates, includingin combination with other drugs and therapies;•the potential advantages of our product candidates;•the rate and degree of market acceptance and clinical utility of our products, if approved;•our estimates regarding the potential market opportunity for our product candidates;•our commercialization, marketing and manufacturing capabilities and strategy;•the initiation, timing, progress and results of our drug target discovery screening programs;•our intellectual property position;•the progress and results of our exclusive global license agreement with CAMP4 Therapeutics Corp., or CAMP4;•our ability to identify, in-license, acquire or develop additional products, product candidat